Möchten Sie immer auf dem neuesten Stand bleiben?

Exton, PA, July 24, 2026 (GLOBE NEWSWIRE) -- The U.S. market for PD-1 inhibitors has entered a new phase of evolution. According to the latest RealTime Dynamix™: PD-1 Inhibition in Solid Tumors...

Exton, PA, July 23, 2026 (GLOBE NEWSWIRE) -- The launch of Bristol Myers Squibb's Sotyktu® (deucravacitinib) is doing more than introducing another treatment option for psoriatic arthritis (PsA), it...

Exton, PA, July 08, 2026 (GLOBE NEWSWIRE) -- The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease...

Exton, PA, July 07, 2026 (GLOBE NEWSWIRE) -- While the treatment landscape for systemic lupus erythematosus (SLE) continues to evolve with increasing biologic adoption and a growing pipeline of...

Exton, PA, June 17, 2026 (GLOBE NEWSWIRE) -- Despite the introduction of new therapies, connective tissue disease-associated interstitial lung disease (CTD-ILD) remains an area of significant unmet...

Exton, PA, June 12, 2026 (GLOBE NEWSWIRE) -- Despite widespread recognition that long-term steroid exposure should be minimized in patients with warm autoimmune hemolytic anemia (w-AIHA), treatment...

Exton, PA, May 28, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the 2026 update of Market Dynamix™: Idiopathic Inflammatory Myopathies (IIM), US, revealing a market increasingly...

Exton, PA, May 27, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients...

Exton, PA, May 21, 2026 (GLOBE NEWSWIRE) -- Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new findings from Spherix Global Insights suggest that operational and...

Exton, PA, May 19, 2026 (GLOBE NEWSWIRE) -- Data collected between May 4 and May 9, 2026 through Spherix Global Insights’ Launch Dynamix™ service suggest Bristol Myers Squibb’s Sotyktu...